Status:
COMPLETED
EUS-RFA for Unresectable Pancreatic Cancer
Lead Sponsor:
First People's Hospital of Hangzhou
Conditions:
Pancreatic Ductal Adenocarcinoma
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events....
Detailed Description
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.
Eligibility Criteria
Inclusion
- age 20 to 80 years old. ② unresectable PDAC based on review of abdominal cross-sectional imaging (CT or MRI) and cytology/ histology results. ③Intolerance to chemotherapy due to side effects or patient's comorbidities.
Exclusion
- Pregnancy or breast-feeding；②ECOG performance status 3 or 4；③Patients with distant metastases or malignant ascites, life expectancy less than 3 months.
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 25 2021
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT04310111
Start Date
March 1 2020
End Date
August 25 2021
Last Update
August 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 31006